Sort
51,593 grants matching “hepatitis”
Structural and Mechanistic basis for RNA Silencing
$692,300Ian John Macrae · Scripps Research Institute, The · R35 · FY2025 · GM
Structural and Mechanistic basis for RNA Silencing
$692,300Ian John Macrae · Scripps Research Institute, The · R35 · FY2024 · GM
The role of lymphatics in cholestatic liver disease
$692,244Yasuko Iwakiri · Yale University · R01 · FY2025 · DK
The role of lymphatics in cholestatic liver disease
$692,243Yasuko Iwakiri · Yale University · R01 · FY2024 · DK
Characterization of Mucosal Lymphocytes
$692,203Richard S Blumberg · Brigham And Women'S Hospital · R37 · FY2009 · DK
Structural characterization of native HBV capsids and virions from human cells
$692,089Che-Yen Wang · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2025 · AI
Structural characterization of native HBV capsids and virions from human cells
$692,089Che-Yen Wang · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2024 · AI
Early-Stage Chronic Kidney Disease in HIV-infected Individuals
$692,038Gregory M Lucas · Johns Hopkins University · R01 · FY2015 · DA
Biomarkers for treatment monitoring and prognostication of disorders of hepatic copper metabolism
$692,025Michael L Schilsky · Yale University · R01 · FY2024 · DK
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer
$692,001Hyung L Kim · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer
$692,001Hyung L Kim · Cedars-Sinai Medical Center · R01 · FY2025 · CA
When pandemics collide: The intersection of the opioid crisis, COVID-19 and HIV pandemics among people who inject drugs in the United States
$691,854Becky Lynn Genberg · Johns Hopkins University · R01 · FY2023 · DA
The regulation of fasting glucose metabolism in people with and without prediabetes
$691,844Adrian Vella · Mayo Clinic Rochester · R01 · FY2024 · DK
Behavioral Science and Biostatistics Resource Core for Alcohol-HIV Research
$691,840Christopher W. Kahler · Brown University · U24 · FY2016 · AA
ECONOMIC COST OF DRUG USE AND ABUSE
$691,734Rosalie Pacula · Rand Corporation · R01 · FY2008 · DA
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
$691,653Monika Sarkar · University Of California, San Francisco · R01 · FY2025 · DK
Optimizing PrEP regimens for pregnant women in sub-Saharan Africa
$691,647Benjamin H Chi · Univ Of North Carolina Chapel Hill · R01 · FY2022 · AI
PUFAs and gene variation affecting aspirin antiplatelet response
$691,629Kenneth E. Thummel · University Of Washington · P01 · FY2020 · GM
Creation of in vivo active chemical probes for CAMKK2 to treat cancer
$691,617David Harold Drewry · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
Western States Node of the National Drug Abuse Treatment Clinical Trials Network
$691,567James L. Sorensen · University Of California, San Francisco · UG1 · FY2019 · DA
Immune function and the risk of cvd among HIV infected and uninfected veterans
$691,563Matthew S Freiberg · Vanderbilt University Medical Center · R01 · FY2017 · HL
Integrated eHealth for HIV and Substance Use Disorders in Justice-involved Women
$691,541Jaimie Meyer · Yale University · R01 · FY2024 · DA
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis
$691,510Daniel James Rader · University Of Pennsylvania · R01 · FY2020 · DK
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance
$691,240Charles M. Rice · Rockefeller University · R01 · FY2013 · AI
Nutritional Status In HIV Hispanic Drug Abusers
$691,239Janet E Forrester · Tufts University Boston · R01 · FY2006 · DA